Aprea Therapeutics Reports Third Quarter 2022 Financial Results and Provides Update on Business Operations BOSTON, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel synthetic lethality-based cancer...

Aprea Therapeutics Announces Poster Presentation at the 2022 Rivkin Center and American Association for Cancer (AACR) Virtual Ovarian Cancer Research Seminar Series BOSTON, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting...

Aprea Therapeutics to Participate in the 2022 H.C. Wainwright Global Investment Conference BOSTON, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting...